Krsnaa Diagnostics Limited
Krsnaa Diagnostics Limited operates in Healthcare Service Provider, part of the Healthcare sector. It booked ₹271 cr of revenue in its latest quarter (Q2 FY27) and kept 9.1% of sales as profit. It is the 7th largest of 9 Healthcare Service Provider companies we track, by market value.
“The Company is primarily engaged in the business of providing to twelve months as its operating cycle.”
“is to be not only the largest, but also the most trusted diagnostic chain in As we move into FY 2025-26 our India.”
Healthier than 52% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 80–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 29
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
What if I invest in KRSNAA?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹271 cr |
| Other Income | ₹6 cr |
| Total Income | ₹277 cr |
| Cost of Materials | ₹56 cr |
| Purchases of Stock-in-Trade | ₹0 cr |
| Employee Benefit Expense | ₹37 cr |
| Finance Costs | ₹15 cr |
| Depreciation & Amortisation | ₹29 cr |
| Other Expenses | ₹107 cr |
| Total Expenses | ₹244 cr |
| Profit before Tax | ₹33 cr |
| Tax Expense | ₹8 cr |
| Share of JV / Associates | ₹0.4 L |
| Net Profit | ₹25 cr |
| Net margin on total income | 8.9% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 193 cr | 236 cr | 271 cr |
| Total income | 224 cr | 243 cr | 277 cr |
| Expenses | 172 cr | 220 cr | 244 cr |
| Profit before tax | 52 cr | 22 cr | 33 cr |
| Tax | 10 cr | 6 cr | 8 cr |
| Net profit (owners' share) | 42 cr | 17 cr | 25 cr |
| Net margin (owners' share, on revenue) | 21.7% | 7.0% | 9.1% |
| EPS (₹) | 12.86 | 5.10 | 7.64 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd. | ₹1,926 | ₹32,275 cr | 47.4 | 27.0% | 21.2% | — |
| Vijaya Diagnostic Centre Limited | ₹1,447 | ₹14,890 cr | 70.1 | 22.2% | 23.0% | — |
| Metropolis Healthcare Limited | ₹569 | ₹11,791 cr | 52.1 | 15.0% | 12.6% | — |
| Thyrocare Technologies Limited | ₹483 | ₹7,686 cr | 125.8 | 11.5% | 5.9% | — |
| Nephrocare Health Services Limited | ₹625 | ₹6,281 cr | 46.8 | 11.3% | 11.1% | — |
| Suraksha Diagnostic Limited | ₹324 | ₹1,686 cr | 32.4 | 21.3% | 14.8% | — |
| Krsnaa Diagnostics Limitedthis company | ₹486 | ₹1,576 cr | 15.9 | 9.5% | 9.1% | — |
| Health X Platform Limited | ₹281 | ₹895 cr | 87.9 | 1.6% | 0.6% | — |
| Gaudium IVF and Women Health Limited | ₹108 | ₹786 cr | 107.9 | 4.7% | 9.2% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹2 / share | 18 Sep 2026 |
| Dividend | ₹2.75 / share | 12 Sep 2025 |
| Dividend | ₹2.5 / share | 13 Sep 2024 |
| Dividend | ₹2.75 / share | 15 Sep 2023 |
| Dividend | ₹2.5 / share | 15 Sep 2022 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.